Regenosine is developing a first-in-class disease-modifying regenerative therapy for osteoarthritis.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 1, 2021 | Grant | $1.67M | 1 |
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Grant |